BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 24, 2011
View Archived Issues
Dominant negative CXCL8 (IL-8) mutant reduces renal allograft damage
Read More
Switching from agalsidase beta to agalsidase alfa feasible for Fabry's disease
Read More
Eisai receives European approval for Halaven in advanced breast cancer
Read More
Preliminary data from phase III trial support feasibility of rHuPH20-faciliated IGSC therapy
Read More
NeuroPhage plans phase I study of bacteriophage NPT-001 in Alzheimer's disease
Read More
Personalized peptide vaccine shows promise in patients with resistant urothelial carcinoma
Read More
Theravida's THVD-201 reduces symptoms of dry mouth in phase I trial in OAB, phase II study under way
Read More
Efficacy of botulinum toxin type A in idiopathic detrusor overactivity confirmed in large study
Read More
Potential new biomarker for chronic rhinosinusitis with nasal polyps identified / News in Context
Read More
Portsmouth Technologies patents novel hydroxamate histone deacetylase inhibitors
Read More
Synageva BioPharma receives funding for SBC-102 in lysosomal acid lipase deficiency
Read More
Cellular Dynamics and Roche form standard supply agreement for iCell Cardiomyocytes
Read More
OncoTherapy Science initiates gastric cancer vaccine trial in Singapore
Read More
Takeda launches Reminyl for dementia of the Alzheimer's type in Japan
Read More
Phase I/II results for InSite Vision's ISV-303 encouraging for cataract postsurgery pain
Read More
Xoma reports phase II data for XOMA-052 in type 2 diabetes
Read More
Starpharma completes all patient follow-up visits in phase II trial of VivaGel
Read More
SYGNIS to continue phase II AXIS 2 study of AX-200 in acute ischemic stroke
Read More
Ambrilia Biopharma enters into agreement with ZBx for PSP-94
Read More
Rexahn reaches 33% enrollment in phase IIb trial of Serdaxin in major depressive disorder
Read More
Takeda submits Japanese NDA for TAK-536 in hypertension
Read More
Phase III elvitegravir trial in HIV meets primary objective
Read More
Graceway receives Canadian approval for topical genital warts treatment Vyloma 3.75%
Read More
KaloBios begins phase I trial of anti-EphA3 monoclonal antibody in hematologic malignancies
Read More